South Korea’s SK Inc., Develops Its CDMO Capabilities via Investment in the Center for Breakthrough Medicines
To come along with the clinical trials conducted by one of SK Inc.’s child companies, SK biopharmaceuticals, SK is taking a wider view of the future and investing in CMO infrastructure with CBM. This is already in the wake of the 2021 creation of SK Pharmateco and acquiring of AMPAC Fine Chemicals, SK biotek, SK biotech Ireland, and Yposkesi.
It's free! Log in now to read